Back
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
Journal article

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).

  • Ascierto PA Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com.
  • Puzanov I Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Agarwala SS Temple University School of Medicine, Philadelphia, PA, USA.
  • Blank C Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Carvajal RD Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
  • Demaria S Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
  • Dummer R Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
  • Ernstoff M Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, State University, Buffalo, NY, USA.
  • Ferrone S Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Fox BA Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA.
  • Gajewski TF Department of Pathology, University of Chicago, Chicago, IL, USA.
  • Garbe C Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
  • Hwu P Department of Melanoma Medical Oncology, Division of Cancer Medicine, Anderson Cancer Center, Houston, TX, USA.
  • Lo RS Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Long GV Melanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Luke JJ Medicine University of Chicago, Chicago, IL, USA.
  • Osman I The Interdisciplinary Melanoma Program, New York University Langone Medical Center, NYU Grossman Medical School, New York, NY, USA.
  • Postow MA Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Sullivan RJ Melanoma Program, Mass General Cancer Center, Boston, MA, USA.
  • Taube JM Division of Dermatopathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Trinchieri G Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Zarour HM Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
  • Caracò C Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
  • Thurin M Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, MD, USA.
Show more…
  • 2020-09-07
Published in:
  • Journal of translational medicine. - 2020
Adjuvant
Anti-CTLA-4
Anti-PD-1
BRAF inhibitor
Biomarkers
CAR-T
Combination strategies
Immunotherapy
MEK inhibitor
Melanoma
Neoadjuvant
Target therapy
English The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understanding of the tumor microenvironment (TME) and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. The approval of new immune and targeted therapies has further improved outcomes for patients with advanced melanoma and other combination modalities are also being explored such as chemotherapy, radiotherapy, electrochemotherapy and surgery. In addition, different strategies of drugs administration including sequential or combination treatment are being tested. Approaches to overcome resistance and to potentiate the immune response are being developed. Increasing evidence emerges that tissue and blood-based biomarkers can predict the response to a therapy. The latest findings in melanoma research, including insights into the tumor microenvironment and new biomarkers, improved understanding of tumor immune response and resistance, novel approaches for combination strategies and the role of neoadjuvant and adjuvant therapy, were the focus of discussions at the Melanoma Bridge meeting (5-7 December, 2019, Naples, Italy), which are summarized in this report.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/39295
Statistics
Document views: 31 File downloads: